Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01855451
Other study ID # TROG 12.01
Secondary ID ACTRN12613000279
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 3, 2013
Est. completion date August 23, 2023

Study information

Verified date November 2022
Source Trans Tasman Radiation Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A standard treatment for patients with head and neck cancer is radiation given with high doses of a chemotherapy drug called cisplatin, given every 3 weeks during the radiation. This treatment is effective but can significantly increase side effects such as difficulty with swallowing, a sore mouth, fatigue, hearing loss, ringing in the ears and kidney failure. In Australia, a commonly used treatment HPV-Associated Oropharyngeal Squamous Cell Carcinoma is a lower dose of cisplatin given weekly during the radiation. The high dose and low dose schedules result in a similar total dose of cisplatin being given during the radiation, but it is thought that the weekly schedule results in fewer side effects while maintaining effectiveness. Another approach widely used around the world for patients with head and neck cancer, is to administer the antibody, cetuximab, weekly during radiation. Cetuximab has a very different side effect profile to cisplatin, and has been reported to result in less exacerbation of radiation related side effects. Both cetuximab and cisplatin can reduce the growth of a cancer and increase the effectiveness of radiation. Both cisplatin and cetuximab appear to be effective treatments in combination with radiation, but have not been directly compared. The purpose of this study is to compare the treatment related side effects (both acute and longer term) between the cisplatin and cetuximab regimens. Both treatments would be given with the same dose of radiation therapy over 7 weeks. The results of this trial will help determine the optimal treatment for patients with HPV-Associated Oropharyngeal Squamous Cell Carcinoma.


Description:

Human Papilloma Virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in incidence and has an improved prognosis compared to other head and neck malignancies when treated with standard combination chemoradiation. The current standard regimen of high dose cisplatin and Radiation Therapy (RT) for head and neck cancer patients results in significant toxicity and is at the limits of tolerance. The excellent prognosis of patients with HPV-positive OPSCC raises concerns about overtreatment with the current standard of care, resulting in unnecessary acute and late morbidity. Therefore, investigation of chemo-sparing or chemo-modified regimens with RT for HPV-associated OPSCC that do not compromise efficacy is warranted. A number of regimens less intensive than high dose cisplatin are being used in clinical practice for patients with good prognosis HPV OPSCC, but no comparative trials have been performed in this population. The trial population will be restricted to low risk HPV-associated OPSCC. Trial Arms: A- RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy) B- RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy) Hypothesis: In patients with locally advanced HPV-associated OPSCC, those treated with weekly cetuximab and conventionally fractionated radiotherapy will experience less acute symptom severity than patients receiving weekly cisplatin and conventionally fractionated radiotherapy. Patients will be followed weekly during treatment, then at 1, 3, 5, 9, 13 weeks post-treatment and at months 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 42, 48, 54, and 60 post-completion of treatment. Follow-up for the trial will cease when the last patient accrued has a minimum of 2 years follow-up i.e. has attended the 24 months post-treatment review.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 189
Est. completion date August 23, 2023
Est. primary completion date April 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Aged 18 years or older 2. Has provided written Informed Consent for participation in this trial 3. Histologically confirmed squamous cell carcinoma of the oropharynx with p16 positive status confirmed locally by immunohistochemistry 4. Stage III (excluding T1-2N1) or stage IV (excluding T4, N3, and distant metastasis) if smoking history of < /=10 pack years. If > 10 pack years nodal disease must be N0 - N2a. 5. If an excisional biopsy has been performed, patients remain eligible for the study provided there is clinically measurable disease prior to commencing RT. The residual disease should still meet the stage criteria required for the trial e.g. excisional biopsy of a node with residual T3 primary, or tonsillectomy for T1 primary with residual > N2a nodes. 6. No prior treatment for oropharyngeal cancer 7. Adequate haematological, renal, and hepatic function as defined by, 1. Absolute neutrophil count (ANC, segs + bands) > /= 1.5 x 109/L 2. Platelet count > /= 100 x 109/L 3. Total bilirubin < /= 1.5 x upper normal limit 4. ALT < /= 2.5 x upper normal limit 5. Calculated creatinine clearance (Cockcroft-Gault formula) or isotopic GFR > 55ml/min 8. ECOG performance status score of 0-1 9. Participants capable of childbearing are using adequate contraception and intend to continue use of contraception for at least 6 months following completion of treatment 10. Negative pregnancy test within 72 hours prior to randomisation of women who are of childbearing potential 11. Suitable for follow-up for at least 24 months as per trial protocol. 12. Sufficient proficiency in English, cognitive capacity and willingness to complete questionnaires Exclusion Criteria: 1. History of unknown primary of the head and neck 2. T4, N3 or distant metastases 3. Smoking history >10 pack years with N2b or c nodal status 4. Women who are pregnant or lactating. 5. Previous radiotherapy to the area to be treated (excluding superficial radiotherapy for a cutaneous malignancy) 6. Previous cisplatin or carboplatin chemotherapy 7. Prior EGFR targeted therapy of any kind 8. Primary surgery to the affected area (excisional biopsy allowed) 9. Peripheral neuropathy > /= grade 2 (CTCAE v4.0) 10. Sensori-neural hearing impairment >= grade 2 (CTCAE v4.0, hearing impaired, not enrolled on a monitoring program) which may be exacerbated by cisplatin (Audiometric abnormalities without corresponding clinical deafness will not be grounds for exclusion) 11. Tinnitus > /= grade 2 (CTCAE v4.0) 12. History of interstitial lung disease or evidence of interstitial lung disease on pre-registration CT 13. History of myocardial infarction within 12 months prior to study entry, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable arrhythmia, uncontrolled psychotic disorders, active serious infections, active peptic ulcer disease, immunosuppression due to post-organ transplantation or use of immunosuppressants for autoimmune disorders 14. Patients known to be HIV positive 15. Other cancer that was diagnosed: 1. more than 5 years prior to current diagnosis with (i) subsequent evidence of disease recurrence or (ii) clinical expectation of recurrence is greater than 10% or 2. within 5 years of the current diagnosis, with the exception of successfully treated basal cell or squamous cell skin carcinoma, in situ melanoma, or carcinoma in situ of the cervix

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cetuximab

Radiation:
RT (70 Gy in 35 fractions)

Drug:
Cisplatin


Locations

Country Name City State
Australia Flinders Medical Centre Bedford Park South Australia
Australia Chris O'Brien Lifehouse Camperdown New South Wales
Australia Canberra Hospital Canberra Australian Capital Territory
Australia Peter MacCallum Cancer Centre East Melbourne Victoria
Australia Royal Brisbane and Womens Hospital Herston Queensland
Australia Liverpool Hospital Liverpool New South Wales
Australia Austin Hospital Melbourne N. Victoria
Australia Sir Charles Gairdner Nedlands Western Australia
Australia St George Hospital St George New South Wales
Australia Townsville Hospital Townsville Queensland
Australia Riverina Cancer Care Centre Wagga Wagga New South Wales
Australia Calvary Mater Newcastle Waratah New South Wales
Australia Westmead Hospital Westmead New South Wales
Australia Princess Alexandra Hospital Woolloongabba Queensland
New Zealand Auckland City Hospital Auckland
New Zealand Palmerston North Hospital Palmerston

Sponsors (1)

Lead Sponsor Collaborator
Trans Tasman Radiation Oncology Group

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptom Severity The area under curve of symptom severity between weekly cisplatin and Radiotherapy Therapy (RT) versus weekly cetuximab and RT from baseline to week 20 (13 weeks post-completion of radiotherapy) as measured by M.D. Anderson Symptom Inventory - Head and Neck Module (MDASI-HN). 20 weeks
Secondary Symptom severity Symptom severity measured by MDASI-HN (Symptom Interference Score, Symptom Score, Symptom Clusters and individual item scores at individual time points)and by Functional Assessment of Cancer Therapy - Head and Neck (FACT-HN). 24 months
Secondary Interference of symptoms with daily life To compare interference of symptoms with daily life using the MDASI-HN Symptom Interference Score and Quality adjusted life years (QALYs) using the EQ-5D-5L 24 mths
Secondary Psychological distress To compare psychological distress measured by FACT-HN domain scores and depression and anxiety scales of Hospital Anxiety and Depression Scale (HADS) 36 months
Secondary Impact on Health Related Quality of Life 36 months
Secondary Swallowing dysfunction To compare swallowing dysfunction by Functional swallowing outcome (video fluoroscopy), CTCAE (v4.0) dysphagia, MDASI and FACT questionnaires, enteral feeding rates. 12 months
Secondary Speech and dietary function To compare speech and dietary function as measured by the Performance Status Scale for Head & Neck Cancer Patients (PSS-HN) 36 months
Secondary Clinician-assessed acute and late toxicity To compare clinician-assessed acute and late toxicity using toxicity grading (CTCAE v4.0) - reported as worst toxicity and as overall acute toxicity burden (T-score) 60 months
Secondary Rate of enteral feeding To compare rate of enteral feeding at 12 months following treatment using Barnard's exact test for the comparison of two proportions 12 months
Secondary Hearing impairment To compare hearing impairment, as measured by total score of the Hearing Handicap Inventory for adults, screening version (HHIA-S) and audiometry (results will be evaluated according to CTCAE 3 and 4 criteria, Brock criteria, Chang criteria and SIOP Boston Ototoxicity Scale). 24 months
Secondary Time to locoregional failure To compare time to locoregional failure primarily determined by evidence of progression or recurrence clinically or radiologically 36 months
Secondary Failure-free survival To compare failure-free survival by clinical and radioloigical assessments 36 months
Secondary Overall survival To compare overall survival by clinical assessment. 60 months
Secondary Pattern of disease failure Pattern of disease failure (locoregional [recurrence at primary tumour site and/or regional nodes], distant, both) as assessed radiologically. 36 months
Secondary Complete response rate To compare FDG-PET-CT complete response rate at week 20 20 weeks
Secondary Cost of health resource utilisation To compare cost of health resource utilisation via questionnaires EQ-5D-5L and RTOG return to work questionnaire. 24 months
Secondary Work status and time to return to work To compare work status and time to return to work by RTOG questionnaire 24 months
Secondary Potential prognostic markers To correlate several potential prognostic markers (including but not limited to EGFR protein level, EGFR copy number, ERCC1, plasma hepatocyte growth factor level, and plasma IL-8) with failure-free survival, overall survival and time to locoregional failure. 60 months
See also
  Status Clinical Trial Phase
Completed NCT02113878 - Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Phase 1
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Active, not recruiting NCT05524025 - The SPOT-HPV Study
Recruiting NCT05600842 - De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Recruiting NCT05973487 - A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors Phase 1
Terminated NCT05061940 - This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Recruiting NCT05119036 - Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma Phase 2
Recruiting NCT06088381 - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Phase 2
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2
Recruiting NCT05814549 - A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
Active, not recruiting NCT04260126 - Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC Phase 2
Recruiting NCT05108870 - TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers Phase 1/Phase 2
Recruiting NCT05307939 - A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) Phase 2
Active, not recruiting NCT04871490 - Improving Detection and Early Action for HPV-positive Oropharynx Cancer N/A
Not yet recruiting NCT06319963 - A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer Phase 1/Phase 2
Terminated NCT03601507 - Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer Phase 2
Terminated NCT04301011 - Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05639972 - E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers Phase 1/Phase 2
Active, not recruiting NCT03978689 - A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma Phase 1